SCHEMBL18627912

SCHEMBL18627912

CC(C)C1C(=O)NCCN1c1ncc(-c2cccc(Nc3nccc(N4CCOCC4)n3)c2)o1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMG1 Q96Q15 8/20 0.44
▸ CDK1 P06493 3/20 0.44
▸ CDK2 P24941 3/20 0.44
▸ SYK P43405 1/20 0.44
▸ MTOR P42345 3/20 0.43
▸ CAMK2D Q13557 1/20 0.39
▸ JAK2 O60674 3/20 0.38
▸ TYK2 P29597 2/20 0.38
▸ JAK3 P52333 2/20 0.38
▸ CCNT1 O60563 3/20 0.38
▸ CDK9 P50750 3/20 0.38
▸ BRAF P15056 1/20 0.38
▸ JAK1 P23458 1/20 0.38
▸ IDH1 O75874 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ BCR P11274 1/20 0.37
▸ ZAP70 P43403 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18627930 0.95 SYK (0.43) SMG1CDK1CDK2SYKMTOR
SCHEMBL18627959 0.93 SYK (0.42) SMG1CDK1CDK2SYKMTOR
SCHEMBL18627925 0.90 SYK (0.46) SMG1CDK1CDK2SYKMTOR
SCHEMBL18627908 0.88 SYK (0.47) SMG1CDK1CDK2SYKCCNT1
SCHEMBL18627910 0.88 SYK (0.47) SMG1CDK1CDK2SYKCCNT1
SCHEMBL18627951 0.88 SYK (0.47) SMG1CDK1CDK2SYKCCNT1
SCHEMBL18627919 0.88 SYK (0.43) SMG1CDK1CDK2SYKMTOR
SCHEMBL18627918 0.88 SYK (0.45) SMG1CDK1CDK2SYKJAK2
SCHEMBL18627896 0.86 SYK (0.43) SMG1CDK1CDK2SYKCCNT1
SCHEMBL18627955 0.86 SYK (0.45) SMG1CDK1CDK2SYKMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350176-B1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2021-04-28 — — EP claimed
US-10392373-B2 Oxazole derivatives that inhibit Syk AB SCIENCE (FR) 2019-08-27 — — US claimed
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2019-02-21 — — US claimed
EP-3144307-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2017-03-22 — — EP claimed
EP-3350176-B1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2021-04-28 — — EP disclosed
US-10392373-B2 Oxazole derivatives that inhibit Syk AB SCIENCE (FR) 2019-08-27 — — US disclosed
US-10392373-B2 Oxazole derivatives that inhibit Syk AB SCIENCE (FR) 2019-08-27 — — US disclosed
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2019-02-21 — — US disclosed
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB SCIENCE (FR) 2019-02-21 — — US disclosed
EP-3144307-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2017-03-22 — — EP disclosed
EP-3144307-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK AB Science (FR) 2017-03-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055230-A1 NOVEL OXAZOLE DERIVATIVES THAT INHIBIT SYK SYK, BTK, LCK SMG1 968/4885CDK1 614/4885CDK2 841/4885
US-10392373-B2 Oxazole derivatives that inhibit Syk SYK, BTK, LCK SMG1 950/4885CDK1 555/4885CDK2 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback